You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

Citation Tools

Article menu

Download PDFPDF

Case report
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Reed-Perino DE, Lai M, Yu EY, et al
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report
Journal for ImmunoTherapy of Cancer 2023;11:e006794. doi: 10.1136/jitc-2023-006794